Bachem Holding AG
BANB
Ранг среди акций
#2516
Bachem Holding AG serves pharmaceutical and biotechnology companies globally,... Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Цена акции
$100.60
Рыночная капитализация
$7.54B
Изменение (1 день)
-1.49%
Изменение (1 год)
49.53%
Страна
CH
Торговля Bachem Holding AG (BANB)
Категория
Healthcare
Выручка компании Bachem Holding AG (BANB)
Выручка на Oct 2026 TTM: 0
Согласно последним финансовым отчетам Bachem Holding AG, текущая выручка компании (TTM) составляет 0. В 2026 году компания получила выручку 0 равна выручке в 2026 году, которая составила 0. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Bachem Holding AG с 2002 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2025 | $875.88M | 30.72% |
| 2024 | $670.05M | -2.39% |
| 2023 | $686.47M | 19.36% |
| 2022 | $575.15M | 4.20% |
| 2021 | $551.97M | 23.34% |
| 2020 | $447.51M | 38.00% |
| 2019 | $324.29M | 12.93% |
| 2018 | $287.17M | 6.98% |
| 2017 | $268.42M | 15.53% |
| 2016 | $232.34M | 11.33% |
| 2015 | $208.69M | 12.70% |
| 2014 | $185.17M | -3.20% |
| 2013 | $191.29M | 11.30% |
| 2012 | $171.87M | 10.72% |
| 2011 | $155.22M | -5.12% |
| 2010 | $163.59M | -7.04% |
| 2009 | $175.99M | -3.60% |
| 2008 | $182.56M | 4.04% |
| 2007 | $175.47M | 24.55% |
| 2006 | $140.88M | 20.66% |
| 2005 | $116.75M | -10.21% |
| 2004 | $130.03M | 11.21% |
| 2003 | $116.92M | 7.90% |
| 2002 | $108.36M | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
